Business Context and Reporting Period
This Form 6-K filing by Enlivex Therapeutics Ltd. (Enlivex) covers the month of December 2025, with a specific report date of December 18, 2025. The filing announces the convening of an Extraordinary General Meeting of Shareholders scheduled for February 3, 2026, at 7:00 p.m. Israel time at the company's principal executive offices in Nes Ziona, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a procedural notice regarding a shareholder meeting and does not contain financial statements or performance data.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The primary event is the administrative scheduling of a shareholder meeting.
Guidance, Outlook, and Risks
Management commentary is limited to the logistical details of the upcoming Extraordinary General Meeting. The filing incorporates by reference the Notice and Proxy Statement (Exhibit 99.1) and Proxy Card (Exhibit 99.2), which contain the specific matters to be voted upon. No specific guidance, outlook, risks, or contingencies are detailed within the body of this Form 6-K text.
Key Facts for Investor Verification
- Verify the specific agenda items and proposals to be voted on by reviewing the attached Notice and Proxy Statement (Exhibit 99.1).
- Confirm the record date for shareholder eligibility, which is typically detailed in the proxy materials but not in this summary text.
- Note that the meeting is scheduled for February 3, 2026, at the company's offices in Nes Ziona, Israel.
- Review the incorporated registration statements (Forms S-8, F-3, F-3MEF) for broader context on the company's capital structure and ongoing offerings.